Envoy Medical, Inc. (COCHW)

Quarterly Report Filed: 2026-05-11

Key Insights

• Cash position improved significantly from $3.7M to $25.3M in Q1 2026, indicating successful capital raise through offerings, though the company remains pre-revenue with only $39K in quarterly revenue.
• Net loss of $4.4M for Q1 2026 was partially offset by $2M in non-cash gains from warrant liability revaluations, masking underlying cash burn of approximately $5.9M in operating losses.
• Warrant liabilities totaling $4.8M (private and public combined) represent significant dilution risk and future volatility in earnings; the company recorded $2M loss on warrant offerings in the quarter alone.
• Operating expenses remain high at $6M annually (run rate) with minimal revenue, indicating the company is in early-stage development with R&D spending of $3.6M per quarter and approximately 2+ years of cash runway at current burn rate.
• Stock count nearly tripled from 28.9M to 76.9M shares outstanding between year-end and Q1, driven by capital raises, creating severe dilution for existing shareholders and suggesting ongoing reliance on equity financing.

Sentiment: Negative Significance: 6/10

View Original Filing →

Current Report Filed: 2026-05-11

Key Insights

• Envoy Medical filed an 8-K solely to disclose Q1 2026 earnings results via press release, indicating a routine quarterly earnings announcement with no material corporate events or strategic developments.
• The company maintains its emerging growth company status, which provides regulatory flexibility but suggests the firm is still in earlier stages of public company maturity.
• The filing contains minimal substantive information beyond referencing an attached press release, making it impossible to assess actual financial performance, revenue trends, or margin changes from the 8-K alone.

Sentiment: Neutral Significance: 2/10

View Original Filing →

Insider Trading Filed: 2026-04-17

Key Insights

• Chas McKhann, a director of Envoy Medical, Inc., acquired 100,000 stock options exercisable at $0.72 per share. This suggests McKhann is bullish on the company's prospects.
• The stock options will vest pro rata over a 3-year period starting May 15, 2026, indicating a long-term commitment from the director.
• Insider buying of this magnitude, especially by a director, is typically viewed as a positive signal by investors about the company's future performance.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-03-31

Key Insights

• Envoy Medical, Inc. has dismissed its previous independent auditor, Grant Thornton LLP, and appointed a new one, EisnerAmper LLP, for the fiscal year ending December 31, 2026.
• The dismissal of Grant Thornton was due to a competitive process, and there were no reported disagreements or reportable events, except for previously disclosed material weaknesses in internal control over financial reporting.
• The appointment of EisnerAmper as the new independent auditor suggests Envoy Medical is taking steps to address the identified internal control issues and improve the quality of its financial reporting.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Current Report Filed: 2026-03-27

Key Insights

• Envoy Medical, Inc. issued a press release on March 23, 2026, reporting its financial results for the fourth fiscal quarter and fiscal year ended December 31, 2025.
• The company's Class A Common Stock and Redeemable Warrants are traded on the Nasdaq Stock Market under the ticker symbols 'COCH' and 'COCHW' respectively.
• Envoy Medical is classified as an emerging growth company, indicating it may have fewer reporting requirements compared to more established public companies.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Annual Report Filed: 2026-03-23

Key Insights

• Envoy Medical is a medical device company focused on developing and commercializing cochlear implants and middle ear implants, which have significant growth potential in the hearing loss market.
• The company's flagship products, the Acclaim CI and Esteem FI-AMEI, have received regulatory approvals and are generating revenue, although the company has yet to achieve profitability.
• Envoy Medical faces competition from larger, established medical device companies and needs to continue investing in R&D and marketing to drive adoption of its products and increase its market share.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-02-27

Key Insights

• Envoy Medical, Inc. has regained compliance with the Nasdaq Listing Rule 5550(b)(2), allowing it to maintain its listing on the Nasdaq exchange.
• The company will be subject to a one-year discretionary panel monitor by Nasdaq, indicating additional scrutiny and oversight from the exchange.
• The press release announcing the Nasdaq compliance confirmation suggests a positive development for the company, though the specific details of the prior non-compliance are not provided.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-17

Key Insights

• Insider Robert Potashnick purchased 212,500 shares of Envoy Medical's Class A common stock at $0.40 per share, indicating his confidence in the company's prospects.
• Potashnick also received 127,500 and 212,500 warrants to purchase additional Class A shares at $0.40 per share, suggesting he believes the stock is undervalued.
• The options and warrants are subject to shareholder approval and vesting schedules, indicating Potashnick's long-term commitment to Envoy Medical.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-02-17

Key Insights

• Mona Chetan Patel, a director of Envoy Medical, Inc., acquired 312,500 shares of Class A common stock through the exercise of warrants at $0.4 per share, increasing her direct beneficial ownership to 332,500 shares.
• The company granted Patel two additional stock options, one for 25,000 shares at an exercise price of $2.4 and another for 25,000 shares at an exercise price of $0.813, both with long-term vesting schedules.
• The warrant exercises and stock option grants suggest Patel's confidence in the company's long-term prospects and alignment with shareholder interests.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-17

Key Insights

• The reporting person, Susan Kantor, acquired 96,150 shares of Envoy Medical, Inc. (COCHW) at $0.4 per share on 02/12/2026, increasing her direct beneficial ownership to 174,037 shares.
• In addition to the share purchase, Kantor also holds 62,500 stock options with an exercise price of $2.4 and 62,500 stock options with an exercise price of $0.813, as well as 57,690 and 96,150 warrants with an exercise price of $0.4.
• The warrant acquisitions are subject to shareholder approval and have various expiration dates tied to regulatory milestones for Envoy Medical's Acclaim CI Device.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-02-17

Key Insights

• The reporting person, Charles Brynelsen, has purchased 1 million shares of Envoy Medical's Class A common stock at $0.4 per share, indicating insider confidence in the company.
• Brynelsen also holds 62,500 stock options with an exercise price of $2.4, as well as 600,000 and 1,000,000 warrants with an exercise price of $0.4, further increasing his stake in the company.
• The warrants are exercisable upon shareholder approval, with the Series A-1 warrants expiring two years from the initial exercise date or 30 days after the company submits a Premarket Approval Application to the FDA, and the Series A-2 warrants expiring five years from the initial exercise date or 30 days after the company receives FDA approval for its Acclaim CI Device.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-02-17

Key Insights

• Brent T. Lucas, the CEO of Envoy Medical, Inc., has acquired 62,500 shares of the company's Class A common stock at $0.40 per share, increasing his direct ownership to 297,090 shares.
• Lucas also holds stock options and warrants that could potentially increase his beneficial ownership to 1,250,236 shares of Class A common stock.
• The warrant acquisitions are subject to shareholder approval, indicating the company may be seeking to raise additional capital or expand its operations.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-17

Key Insights

• The reporting person, Glen A. Taylor, has made a substantial purchase of 18,750,000 shares of Class A common stock in Envoy Medical, Inc. at $0.4 per share.
• Taylor also holds indirect beneficial ownership of 2,526,058 shares through Taylor Sports Group and 4,810,384 shares through GAT Funding, LLC, indicating a significant stake in the company.
• The company has granted the reporting person 11,250,000 Series A-1 warrants and 18,750,000 Series A-2 warrants, which are exercisable upon stockholder approval and tied to key milestones related to the company's Acclaim cochlear implant product.

Sentiment: Positive Significance: 8/10

View Original Filing →

Current Report Filed: 2026-02-13

Key Insights

• Envoy Medical is conducting a best efforts public offering of common stock, pre-funded warrants, and two series of common warrants, raising significant capital to support its operations.
• Certain company insiders, including directors, officers, and a major shareholder, participated in the offering, purchasing a substantial portion of the shares and warrants at the same price as other investors.
• The company has agreed to seek shareholder approval for the issuance of shares upon exercise of the common warrants within 90 days, and to continue calling meetings every 90 days until approval is obtained.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-02-11

Key Insights

• Envoy Medical, Inc. granted stock options to its Chief Executive Officer and Interim Chief Financial Officer under the company's 2023 Equity Incentive Plan, aligning their interests with shareholders.
• The options have an exercise price of $0.53 per share, with 25% vesting after one year and the remainder vesting pro rata over the following 36 months, incentivizing long-term value creation.
• As an emerging growth company, Envoy Medical may benefit from the extended transition period for complying with new or revised financial accounting standards, providing flexibility to focus on growth initiatives.

Sentiment: Positive Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-02-09

Key Insights

• The reporting person, Robert Potashnick, acquired 15,000 stock options as the Interim CFO of Envoy Medical, Inc. This suggests insider confidence in the company's future performance.
• The options have a 10-year term and vest over 3 years, indicating a long-term commitment from the Interim CFO.
• The exercise price of $0.53 per share is below the current market price, potentially signaling the Interim CFO believes the stock is undervalued.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-09

Key Insights

• Brent T. Lucas, the Chief Executive Officer of Envoy Medical, Inc., has engaged in a significant stock transaction, disposing of 234,590 shares of Class A Common Stock.
• Lucas also holds stock options and warrants that provide him the right to acquire additional 1,089,736 shares of Class A Common Stock, suggesting he maintains a substantial equity stake in the company.
• The company granted Lucas 200,000 additional stock options, which vest over a 3-year period, indicating his continued leadership role and the board's confidence in his management.

Sentiment: Neutral Significance: 6/10

View Original Filing →

Current Report Filed: 2025-12-29

Key Insights

• Envoy Medical extended the expiration date of 1,125,499 outstanding Shortfall Warrants from December 31, 2025 to December 31, 2026, providing warrant holders additional time to exercise.
• The exercise price of the Shortfall Warrants is determined based on a volume weighted average price (VWAP) formula, subject to a minimum price of $1.50 per share, potentially limiting the upside for warrant holders.
• The issuance and resale of the shares underlying the Shortfall Warrants have been registered, providing liquidity for the warrant holders.

Sentiment: Neutral Significance: 4/10

View Original Filing →